Share Price and Basic Stock Data
Last Updated: November 15, 2025, 4:10 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Suven Life Sciences Ltd operates within the pharmaceuticals sector and has shown significant fluctuations in its revenue over the years. In the financial year ending March 2025, the company reported sales of ₹7 Cr, a decline from ₹12 Cr in FY 2024 and a further drop from ₹14 Cr in FY 2023. This consistent decrease in sales raises concerns about the company’s operational effectiveness and market competitiveness. In recent quarters, sales figures have remained low, with ₹4 Cr recorded in both June 2022 and June 2023, but dropping to as low as ₹1 Cr projected for June 2024. The trailing twelve months (TTM) revenue stood at ₹8 Cr, indicating a downward trend compared to previous periods. Such performance contrasts with typical industry expectations, where sustained revenue growth is essential for stability and investor confidence.
Profitability and Efficiency Metrics
Profitability metrics for Suven Life Sciences Ltd present a challenging landscape. The company reported a net profit of -₹184 Cr, with net profit margins consistently negative, reaching -2415.11% in FY 2025. Operating margins also reflect significant distress, with an operating profit margin (OPM) of -2,714%. The company’s return on equity (ROE) was reported at an impressive 87.2%, yet this figure is misleading due to the negative net profit. Efficiency metrics depict a cash conversion cycle of 73 days, which is relatively high, indicating potential issues in managing working capital. The interest coverage ratio (ICR) stood at -3323.53x, underscoring the absence of interest expenses but also highlighting operational inefficiencies that could threaten future profitability.
Balance Sheet Strength and Financial Ratios
Suven Life Sciences Ltd’s balance sheet reveals a mixed picture of financial health. The company has no borrowings, which is a positive indicator of financial prudence and low financial risk. Reserves have dwindled to ₹88 Cr, a significant decline from earlier years, reflecting a reduction in retained earnings amid ongoing losses. The price-to-book value (P/BV) ratio stood at 22.48x, indicating that the stock is highly valued compared to its book value of ₹5.04 per share. This high valuation poses a risk, particularly in the absence of profitability. The current ratio of 3.21x suggests a good liquidity position, allowing the company to cover its short-term liabilities comfortably. However, the return on capital employed (ROCE) was reported at 87.0%, which may not be sustainable given the negative profit margins.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Suven Life Sciences Ltd indicates a strong promoter holding of 67.36%, providing a degree of stability. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold a modest 1.17% and 3.39%, respectively. This limited institutional interest could signal caution among professional investors regarding the company’s financial performance and future prospects. The total number of shareholders stood at 64,921, indicating a relatively engaged retail investor base. However, the declining share price, currently at ₹194, reflects investor skepticism, particularly in light of the company’s consistent losses and declining revenues. The public shareholding at 28.07% suggests that retail investors are also becoming wary, which could impact liquidity and market sentiment.
Outlook, Risks, and Final Insight
The outlook for Suven Life Sciences Ltd is clouded by several risks, including ongoing operational inefficiencies, declining revenues, and negative profitability metrics. The company needs to implement strategic measures to reverse its downward trajectory, such as enhancing operational efficiencies and exploring new revenue streams. The absence of debt provides a buffer, yet the dwindling reserves raise concerns about future investments and growth capabilities. If the company can stabilize its operations and improve its financial performance, it may regain investor confidence. Conversely, sustained losses and increasing operational challenges could lead to further declines in market valuation and shareholder sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Suven Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 247/84.3 | 32.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,870 Cr. | 447 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.1 Cr. | 26.0 | 29.1/17.0 | 90.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.74 Cr | 1,190.19 | 53.59 | 202.45 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 4 | 3 | 3 | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 |
| Expenses | 25 | 26 | 55 | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 |
| Operating Profit | -21 | -22 | -52 | -32 | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 |
| OPM % | -596% | -494% | -1,719% | -1,208% | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% |
| Other Income | 6 | 0 | 2 | 6 | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 |
| Profit before tax | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 |
| EPS in Rs | -0.75 | -1.06 | -2.34 | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 |
Last Updated: August 20, 2025, 2:50 am
Below is a detailed analysis of the quarterly data for Suven Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Expenses, as of Jun 2025, the value is 53.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 8.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -51.00 Cr.. The value appears to be declining and may need further review. It has decreased from -44.00 Cr. (Mar 2025) to -51.00 Cr., marking a decrease of 7.00 Cr..
- For OPM %, as of Jun 2025, the value is -2,714.00%. The value appears strong and on an upward trend. It has increased from -2,981.00% (Mar 2025) to -2,714.00%, marking an increase of 267.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -52.00 Cr.. The value appears to be declining and may need further review. It has decreased from -44.00 Cr. (Mar 2025) to -52.00 Cr., marking a decrease of 8.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears to be declining and may need further review. It has decreased from -44.00 Cr. (Mar 2025) to -52.00 Cr., marking a decrease of 8.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.36. The value appears to be declining and may need further review. It has decreased from -2.01 (Mar 2025) to -2.36, marking a decrease of 0.35.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:21 am
| Metric | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 6 |
| Expenses | 105 | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 219 |
| Operating Profit | 13 | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -214 |
| OPM % | 11% | 31% | 20% | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,638% |
| Other Income | 3 | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 7 |
| Interest | 5 | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 |
| Profit before tax | 6 | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -212 |
| Tax % | -32% | 28% | 26% | 29% | 37% | 15,038% | -11% | -7% | 0% | 0% | -1% | 0% | |
| Net Profit | 8 | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -212 |
| EPS in Rs | 0.48 | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -9.56 |
| Dividend Payout % | 35% | 7% | 35% | 15% | 15% | -80% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.94% | 20.83% | 42.53% | -119.35% | -291.67% | 23.40% | -69.44% | 3.28% | 11.02% | -53.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 54.78% | 21.70% | -161.88% | -172.31% | 315.07% | -92.85% | 72.72% | 7.74% | -64.35% |
Suven Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -12% |
| 3 Years: | -17% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -24% |
| 3 Years: | -12% |
| TTM: | -58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 36% |
| 3 Years: | 43% |
| 1 Year: | 40% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -62% |
| 3 Years: | -55% |
| Last Year: | -87% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: June 16, 2025, 11:16 am
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 |
| Reserves | 95 | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 |
| Borrowings | 55 | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 |
| Other Liabilities | 38 | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 |
| Total Liabilities | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 |
| Fixed Assets | 110 | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 |
| CWIP | 4 | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
| Investments | 2 | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 |
| Other Assets | 83 | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 |
| Total Assets | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 |
Below is a detailed analysis of the balance sheet data for Suven Life Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
- For Reserves, as of Mar 2025, the value is 88.00 Cr.. The value appears to be declining and may need further review. It has decreased from 248.00 Cr. (Mar 2024) to 88.00 Cr., marking a decrease of 160.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 11.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 135.00 Cr.. The value appears to be improving (decreasing). It has decreased from 285.00 Cr. (Mar 2024) to 135.00 Cr., marking a decrease of 150.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 60.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2024) to 60.00 Cr., marking an increase of 32.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 54.00 Cr..
- For Other Assets, as of Mar 2025, the value is 53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 181.00 Cr. (Mar 2024) to 53.00 Cr., marking a decrease of 128.00 Cr..
- For Total Assets, as of Mar 2025, the value is 135.00 Cr.. The value appears to be declining and may need further review. It has decreased from 285.00 Cr. (Mar 2024) to 135.00 Cr., marking a decrease of 150.00 Cr..
Notably, the Reserves (88.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -42.00 | 50.00 | 19.00 | 58.00 | 164.00 | -17.00 | -122.00 | -85.00 | -125.00 | -128.00 | -129.00 | -166.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 28 | 39 | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Inventory Days | 200 | 165 | 183 | 222 | 329 | 0 | ||||||
| Days Payable | 157 | 89 | 78 | 91 | 134 | |||||||
| Cash Conversion Cycle | 154 | 105 | 144 | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 |
| Working Capital Days | 139 | 49 | 55 | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 |
| ROCE % | 8% | 13% | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 694 | 0.06 | 0.01 | 694 | 2025-04-22 17:25:19 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Diluted EPS (Rs.) | -7.37 | -4.82 | -6.63 | -9.57 | -5.67 |
| Cash EPS (Rs.) | -7.10 | -4.52 | -5.12 | -8.09 | -5.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.04 | 12.38 | 17.21 | 6.61 | 8.49 |
| Revenue From Operations / Share (Rs.) | 0.30 | 0.53 | 0.62 | 0.81 | 1.06 |
| PBDIT / Share (Rs.) | -7.10 | -4.90 | -5.39 | -8.05 | -5.68 |
| PBIT / Share (Rs.) | -7.37 | -5.20 | -5.69 | -8.35 | -6.02 |
| PBT / Share (Rs.) | -7.37 | -4.86 | -5.42 | -8.39 | -6.09 |
| Net Profit / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| NP After MI And SOA / Share (Rs.) | -7.37 | -4.82 | -5.42 | -8.39 | -5.67 |
| PBDIT Margin (%) | -2326.94 | -914.01 | -867.37 | -988.42 | -536.50 |
| PBIT Margin (%) | -2414.41 | -969.62 | -915.70 | -1025.51 | -568.75 |
| PBT Margin (%) | -2415.11 | -907.20 | -873.52 | -1029.98 | -574.80 |
| Net Profit Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| NP After MI And SOA Margin (%) | -2415.11 | -898.63 | -873.52 | -1029.98 | -535.31 |
| Return on Networth / Equity (%) | -146.14 | -38.91 | -31.51 | -126.88 | -66.80 |
| Return on Capital Employeed (%) | -143.86 | -41.77 | -32.81 | -121.80 | -68.13 |
| Return On Assets (%) | -118.90 | -36.88 | -30.41 | -112.92 | -56.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
| Current Ratio (X) | 3.21 | 18.99 | 22.61 | 8.01 | 6.45 |
| Quick Ratio (X) | 3.20 | 18.94 | 22.61 | 8.01 | 6.45 |
| Inventory Turnover Ratio (X) | 14.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -3323.53 | -674.71 | -406.21 | -220.85 | -88.68 |
| Interest Coverage Ratio (Post Tax) (X) | -3448.46 | -709.43 | -428.84 | -229.14 | -87.49 |
| Enterprise Value (Cr.) | 2435.23 | 2010.22 | 872.72 | 1343.38 | 849.81 |
| EV / Net Operating Revenue (X) | 365.88 | 171.92 | 64.46 | 113.42 | 63.05 |
| EV / EBITDA (X) | -15.72 | -18.81 | -7.43 | -11.47 | -11.75 |
| MarketCap / Net Operating Revenue (X) | 371.55 | 185.94 | 78.07 | 113.85 | 66.48 |
| Price / BV (X) | 22.48 | 8.05 | 2.82 | 14.02 | 8.30 |
| Price / Net Operating Revenue (X) | 371.56 | 185.97 | 78.08 | 113.85 | 66.48 |
| EarningsYield | -0.06 | -0.04 | -0.11 | -0.09 | -0.08 |
After reviewing the key financial ratios for Suven Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 5. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For Cash EPS (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 3. It has decreased from -4.52 (Mar 24) to -7.10, marking a decrease of 2.58.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.04. It has decreased from 12.38 (Mar 24) to 5.04, marking a decrease of 7.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.30. It has decreased from 0.53 (Mar 24) to 0.30, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -7.10. This value is below the healthy minimum of 2. It has decreased from -4.90 (Mar 24) to -7.10, marking a decrease of 2.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -5.20 (Mar 24) to -7.37, marking a decrease of 2.17.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 0. It has decreased from -4.86 (Mar 24) to -7.37, marking a decrease of 2.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.37. This value is below the healthy minimum of 2. It has decreased from -4.82 (Mar 24) to -7.37, marking a decrease of 2.55.
- For PBDIT Margin (%), as of Mar 25, the value is -2,326.94. This value is below the healthy minimum of 10. It has decreased from -914.01 (Mar 24) to -2,326.94, marking a decrease of 1,412.93.
- For PBIT Margin (%), as of Mar 25, the value is -2,414.41. This value is below the healthy minimum of 10. It has decreased from -969.62 (Mar 24) to -2,414.41, marking a decrease of 1,444.79.
- For PBT Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 10. It has decreased from -907.20 (Mar 24) to -2,415.11, marking a decrease of 1,507.91.
- For Net Profit Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 5. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -2,415.11. This value is below the healthy minimum of 8. It has decreased from -898.63 (Mar 24) to -2,415.11, marking a decrease of 1,516.48.
- For Return on Networth / Equity (%), as of Mar 25, the value is -146.14. This value is below the healthy minimum of 15. It has decreased from -38.91 (Mar 24) to -146.14, marking a decrease of 107.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is -143.86. This value is below the healthy minimum of 10. It has decreased from -41.77 (Mar 24) to -143.86, marking a decrease of 102.09.
- For Return On Assets (%), as of Mar 25, the value is -118.90. This value is below the healthy minimum of 5. It has decreased from -36.88 (Mar 24) to -118.90, marking a decrease of 82.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.03. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Current Ratio (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has decreased from 18.99 (Mar 24) to 3.21, marking a decrease of 15.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.20. This value exceeds the healthy maximum of 2. It has decreased from 18.94 (Mar 24) to 3.20, marking a decrease of 15.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.07. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 14.07, marking an increase of 14.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -3,323.53. This value is below the healthy minimum of 3. It has decreased from -674.71 (Mar 24) to -3,323.53, marking a decrease of 2,648.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3,448.46. This value is below the healthy minimum of 3. It has decreased from -709.43 (Mar 24) to -3,448.46, marking a decrease of 2,739.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,435.23. It has increased from 2,010.22 (Mar 24) to 2,435.23, marking an increase of 425.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 365.88. This value exceeds the healthy maximum of 3. It has increased from 171.92 (Mar 24) to 365.88, marking an increase of 193.96.
- For EV / EBITDA (X), as of Mar 25, the value is -15.72. This value is below the healthy minimum of 5. It has increased from -18.81 (Mar 24) to -15.72, marking an increase of 3.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 371.55. This value exceeds the healthy maximum of 3. It has increased from 185.94 (Mar 24) to 371.55, marking an increase of 185.61.
- For Price / BV (X), as of Mar 25, the value is 22.48. This value exceeds the healthy maximum of 3. It has increased from 8.05 (Mar 24) to 22.48, marking an increase of 14.43.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 371.56. This value exceeds the healthy maximum of 3. It has increased from 185.97 (Mar 24) to 371.56, marking an increase of 185.59.
- For EarningsYield, as of Mar 25, the value is -0.06. This value is below the healthy minimum of 5. It has decreased from -0.04 (Mar 24) to -0.06, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Suven Life Sciences Ltd:
- Net Profit Margin: -2415.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -143.86% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -146.14% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3448.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.2
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.59)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2415.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | info@suvenpharm.com http://www.suvenpharm.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Suven Life Sciences Ltd?
Suven Life Sciences Ltd's intrinsic value (as of 17 November 2025) is 132.35 which is 28.84% lower the current market price of 186.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,240 Cr. market cap, FY2025-2026 high/low of 303/102, reserves of ₹88 Cr, and liabilities of 135 Cr.
What is the Market Cap of Suven Life Sciences Ltd?
The Market Cap of Suven Life Sciences Ltd is 4,240 Cr..
What is the current Stock Price of Suven Life Sciences Ltd as on 17 November 2025?
The current stock price of Suven Life Sciences Ltd as on 17 November 2025 is 186.
What is the High / Low of Suven Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Suven Life Sciences Ltd stocks is 303/102.
What is the Stock P/E of Suven Life Sciences Ltd?
The Stock P/E of Suven Life Sciences Ltd is .
What is the Book Value of Suven Life Sciences Ltd?
The Book Value of Suven Life Sciences Ltd is 12.4.
What is the Dividend Yield of Suven Life Sciences Ltd?
The Dividend Yield of Suven Life Sciences Ltd is 0.00 %.
What is the ROCE of Suven Life Sciences Ltd?
The ROCE of Suven Life Sciences Ltd is 87.0 %.
What is the ROE of Suven Life Sciences Ltd?
The ROE of Suven Life Sciences Ltd is 87.2 %.
What is the Face Value of Suven Life Sciences Ltd?
The Face Value of Suven Life Sciences Ltd is 1.00.